LAT CAB (2021-present)
Funded by the Unitaid LONGEVITY project, the LAT CAB is a new cross-disease long-acting technologies (LAT) community advisory board focused on malaria, the hepatitis C virus, HIV, and latent TB infection.
Materials in this section
About
LAT CAB reviews the state of treatment research, contributes to research protocols, and engages in the research and development process for long-acting technologies for malaria, HCV, HIV, and LTBI. More
LAT CAB: Two New Members
The LAT CAB added two new members: Giten Khwairakpam, from Thailand, and Bakyt Myrzaliev, from Kyrgyzstan. More
Perspectives of People with HCV Lived Experience and Healthcare Providers on Potential Long-Acting Therapies
TAG releases an advocacy brief discussing findings from two surveys conducted among end users and healthcare providers/policy makers to understand their perspectives on potential long-acting therapies for HCV cure. More
Webinar: LONGEVITY Community Engagement: Perspectives of People with HCV and TB Lived Experience and Healthcare Providers on Potential Long-Acting Therapies
TAG and Afrocab hosted a webinar to share findings from surveys conducted under the Unitaid-funded LONGEVITY Project. More
Excitement Builds for Long-Acting TB Treatments, but Research Still at Early Stage
Researchers are working on new long-acting formulations that might, for example, reduce an entire course of TB preventive therapy to a single injection. More
Community Surveys Show Enthusiasm for Long-Acting HCV Cure Research
People living with or at risk of hepatitis C virus, health care providers, and policymakers in low- and middle-income countries showed significant interest in a potential long-acting HCV cure, recent surveys have found. More
Preferences and Feasibility of Long-Acting Technologies for the Treatment of Hepatitis C - A Survey of Patients
A study explores the challenges and opportunities in long-acting HCV treatment across three LMICs: Egypt, Ethiopia and India. More
Preferences and Feasibility of Long-Acting Technologies for the Treatment of Hepatitis C - A Survey of Providers and Policymakers
A study explores the acceptability and feasibility of long-acting HCV treatment in LMICs by surveying HCV treatment prescribers and policymakers. More
Long-Acting Therapies Trials Tracker for Hepatitis C, Opioid Use and Overdose Prevention Therapy, and Malaria
Treatment Action Group releases a trials tracker providing a compilation of ongoing and recently completed clinical trials on long-acting therapies for HCV, malaria, and opioid use and overdose prevention in the R&D pipeline. More
Community Engagement on Microarray Patches
The growing pipeline of MAPs for various infectious diseases prevention and treatment is a cause for engagement with stakeholders involved in health care given their potential to revamp healthcare service delivery. Access useful advocacy resources! More
